4D Molecular Therapeutics' Q3 revenue misses
I'm PortAI, I can summarize articles.
4D Molecular Therapeutics reported Q3 revenue of $90,000, missing analyst expectations of $287,900. The net income also fell short at -$56.88 million compared to the expected -$56.20 million. The company has entered a strategic partnership with Otsuka, receiving $85 million upfront, which is expected to support its cash runway into the second half of 2028. The average analyst rating remains a 'buy' with a 12-month price target of $34.50, reflecting a potential upside of 69.6% from its recent closing price of $10.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments